NextCell publishes its Year-End Report 2020/2021
NextCell Pharma AB (publ) (NXTCL) publishes its Year-End Report for the period September 1, 2020 - August 31, 2021 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report
NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.
Fourth quarter (2021-06-01 until 2021-08-31)
● Operating income amounted to TSEK 1 381 (842).
● Operating result amounted to TSEK -4 475 (-4 877).
● Earnings per share* amounted to SEK -0,13 (-0,22).
● Cash and bank amounted to TSEK 139 168 (21 958).
● Solidity** amounted to 96,4 (88,1) %.
Twelve months (2020-09-01 until 2021-08-31)
● Operating income amounted to TSEK 4 455 (4 166).
● Operating result amounted to TSEK -24 557 (-17 681).
● Earnings per share* amounted to TSEK -0,81 (-0,89).
*Result per share: operating results divided by the average number of shares. Average number of shares for the fourth quarter of 2020/2021
is: 34 379 523 (22 011 081) shares and the average number of shares for the twelve month period is: 30 411 847 (19 864 756).
Number of shares in NextCell as per August 31st 2021 is: 34 379 523 (23 398 334).
**Solidity/Equity ratio: shareholders' equity of the balance sheet total.
Significant events during the fourth quarter of 2020/2021
● NextCell announced in the beginning of June that the first patient with severe pneumonia, as a result of COVID-19 infection, had been treated with ProTrans. The patient was hospitalized at Örebro University Hospital, where the phase Ib study ProTrans19+SE is in progress led by Principal Investigator associate professor Josefin Sundh.
● In the middle of June NextCell announced that a scientific advisory meeting with the European Medicines Agency (EMA) had been held regarding ProTrans and the path forward to a possible marketing approval. The focus was the design of the phase III study, ProTrans-3.
● NextCell announced in the end June a joint venture together with their long-term collaborator and contract manufacture organisation, Polski Bank Komórek Macierzystych (PBKM, FamiCord Group). NextCell acquired ~10 % of shares in the newly started company FamiCordTx through a directed equity issue, raising the capital with 0,5 MEuro in cash. FamiCordTx has exclusively licensed a patent pending CAR-T technology and the tech transfer has been completed. The production of CAR-T cell therapy was awaiting ATMP manufacturing approval before production of CAR-T for clinical trial use could be started.
● In the middle of August NextCell announced that a patent application had been filed for the treatment of Sars-CoV-2 mediated severe pneumonia with ProTrans. NextCell increased the IP protection for the drug candidate ProTrans for the treatment of autoimmune diseases and inflammatory conditions.
● NextCell announced in the end of August that Patrik Fagerholm had been appointed as interim CFO, replacing Sofia Fredriksson.
Significant events after the reporting period
● NextCell announced in the beginning of September that three patients with Covid-19 had been treated with ProTrans in the Swedish study ProTrans19+SE conducted at Örebro University Hospital. As a result, all patients in the low-dose cohort had at point been treated.
● In the beginning of October NextCell announced that their CEO, Dr. Mathias Svahn, was presenting clinical data from the ProTrans-1 and ProTrans-2 diabetes studies.
● NextCell announced in the end of October an updated strategy for ProTrans clinical trial program in type 1 diabetes that will increase the Company’s market potential and reduces its risk.
● NextCell Pharma AB announced in the end of October that the clinical trial ProTrans19+SE can commence to enroll patients in the medium dose group. Three patients having received a low dose ProTrans, have been clinically assessed and evaluated by the Data and Safety Monitoring Board, which allows continuation with medium dose treatment ProTrans for COVID-19 induced ser pneumonia.
This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 29-10-2021 08:00 CET.
For further information, please contact:
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com
Home pages:
NextCell Pharma AB: www.nextcellpharma.com
Cellaviva Sverige: www.cellaviva.se
Cellaviva Danmark: www.cellaviva.dk
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
About NextCell Pharma AB
NextCell is a phase II cell therapy company with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to take ProTrans to market approval via a Phase III study. ProTrans is in addition to diabetes, used in two clinical trials for Covid-19, in Örebro and Montreal (Canada). The company is in the processes of establishing its own GMP facility for production of ProTrans. The GMP facility is expected to be ready for production of smaller quantities of ProTrans in 2023. NextCell furthermore owns 10% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva, Scandinavia's largest stem cell bank for family saving stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).
FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, info@fnca.se.